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The Role of rs1799889 Genetic Variation in Type 2 
Diabetes and Diabetic Nephropathy Risk
Objective: Type 2 diabetes mellitus (T2 DM) represents a complex metabolic disease with genetic heterogeneity and in-
creasing worldwide prevalence. One of the candidate genes associated with T2 DM and diabetic nephropathy (DN) is the 
plasminogen activator inhibitor-1 (PAI-1) gene. The present research aimed to reveal the polymorphism frequencies of the 
PAI-1 gene 4G/5G and to investigate the role of this polymorphism in T2 DM and DN development.
Materials and Methods: The genomic DNA of the 261 individuals was included in this study. The polymerase chain reac-
tion (PCR) method with 4G and 5G allele-particular primers was used to identify the polymorphism of PAI-1 4G/5G. The 
PCR products were evaluated using a CCD camera after 2% agarose gel electrophoresis.
Results: Although the frequencies of the gene genotypes differed statistically significant between 80 patients and 51 patients 
with and without DN, respectively, and the control group, no statistically significant difference was detected between those 
with and without DN. The 5G/5G genotype was found to be significantly higher in the patient group.
Conclusion: The findings suggest that there is a significant correlation between variants of the PAI-1 gene and the risk for 
T2 DM formation.
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INTRODUCTION
Type 2 diabetes mellitus (T2 DM), the prevalence of which is gradually increasing in the world, is one of the 
metabolic diseases (1–3). T2 DM is a disease with genetic heterogeneity and complex interaction of genetic and 
environmental factors (2, 4). T2 DM is a chronic disease with macrovascular and microvascular complications. 
One of its microvascular complications is diabetic nephropathy (DN) (4–6). In DN, glomerular basement mem-
brane thickening and extracellular matrix expansion surrounding mesangial cells occur (7). In addition to playing 
an inhibitory role in extracellular matrix degradation, PAI-1 also initiates diabetes-related complications (8, 9).
Increased PAI-1 expression also plays a significant part in the pathogenesis of DN since it may lead to the devel-
opment of kidney disease by causing extracellular matrix (ECM) accumulation (10).
The PAI-1 gene (accession No. P05121) is located on chromosome 7 (q 21.3–q 22), spans 12.3 kb of DNA, and 
contains 9 exons and 8 introns (10–13). The 4G/5G (rs1799889) polymorphism is located in the PAI-1 gene 
promoter region and is caused by the insertion/deletion variation of guanosine that is located 675 bases upstream 
from the gene’s transcriptional starting point (11). 
In recent years, many studies have indicated the relationship between the rs1799889 polymorphism of the PAI-1 
gene and the risk of diabetes and diabetic complications, by primarily concentrating on diabetic coronary artery 
disease, DN, and diabetic retinopathy (DR) (8, 9, 12–15).
In light of all this information, the current research aimed to identify the frequency of the PAI-1 rs1799889 poly-
morphism and examine its role in T2 DM and DN in the Eastern Black Sea population.
MATERIALS and METHODS
Demographic and clinical variables (e.g., age, BMI, duration of diabetes, gender, smoking, DR, hypertension and 
family history) were recorded for all cases. This study included 131 patients [80 patients without DN (DN-) and 51 
with DN (DN+)] and 130 controls recruited from the Department of Internal Medicine of Artvin State Hospital. 
Approval for the current research was acquired from the local ethics committee of Karadeniz Technical University 
(date: 05.03.2014; number: 2013/134).
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Genomic DNA was isolated using the DNA isolation Kit (EZ-10 
Spin Colon Blood Genomic DNA Minipreps Kit, Biotechnology 
Department Bio Basic Inc., Markham, Ontario, Canada). PCR 
was performed using the following primers (for the 4G allele: 
5’ - GTC TGG ACA CGT GGG GA- 3’; for the 5G allele: 5’ 
- GTC TGG ACA CGT GGG GG- 3’; Downstream primer: 5’ 
- TGC AGC CAG CCA CGT GAT TGT CTA G- 3’; Upstream 
primer: 5’- AAG CTT TTA CCA TGG TAA CCC CTG GT- 3’) 
(Integrated DNA Technologies Inc., Leuven, Belgium) and the 
PCR mixture containing 50 µg genomic DNA, 1XPCR buffer, 
0.2 mM dNTP mixture, 50 pmol allele-specific primers, 50 pmol 
common downstream primer, 2.5 pmol control upstream prim-
er, and 25 U Taq polymerase in a 25 µl total volume (11). The 
following cycling conditions were set: the pre-denaturation step 
of 3 min at 94°C, denaturation of 35 cycles of 1 min at 94°C, 
annealing of 1 min at 54°C, and the extension step of 1 min at 
72°C, followed by the single-cycle final extension step at 72°C 
for five min, using a Thermal Cycler T100 (Bio-Rad, Foster City, 
CA, USA).
The amplified PCR products were run in a 2% agarose gel and 
then imaged with a CCD camera after the execution and the values 
were analyzed using the gel analysis software (LabWorks, Cam-
bridge, UK). The genotyping and classification of the samples into 
one of the three potential genotypes 5G/5G, 4G/4G, or heterozy-
gous 4G/5G were carried out. The homozygous 4G genotype was 
determined based on the PCR result that gave a 139-bp band only 
with the 4G primer but not with the 5G primer. The homozygous 
5G genotype was determined based on the PCR result that gave a 
139-bp band only with the 5G primer but not with the 4G primer. 
The heterozygous 4G/5G genotype was determined based on the 
PCR result that gave a 139-bp band with the 4G and 5G primers.
Statistical Analysis
In this study, all data were statistically analyzed using the SPSS 
ver.21 software. Pearson chi-square test was conducted for the 
analysis of some individual characteristics of controls and patients. 
The Mann-Whitney Rank Sum test was used to analyze some bio-
chemical properties of the control and patient groups. According 
Table 1. Clinical characteristics of the control group, without diabetic nephropathy (DN-) group and with diabetic nephropathy (DN+) group
 DN-  DN+  Control  Statistics 
 n  n  n 
 %  %  %
 - + - + - +
Gender (M/F) 25/55  28/23  44/86  0.012* 
 31.3/68.8  54.9/45.1  33.8/66.2
Smoking 72 8 44 7 127 3 0.514*
 90 10 86.3 13.7 97.7 2.3
Diabetic retinopathy 55 25 33 18 130 0 0.631*
 68.8 31.3 64.7 35.3 100 0
Hypertension 38 42 19 32 122 8 0.249*
 47.5 52.5 37.3 62.7 93.8 6.2
Family history 40 40 24 27 120 10 0.743*
 50 50 47.1 52.9 92.3 7.7
*: Pearson Chi-Square Tests (n-%)
Table 2. Distribution of PAI-1 gene and allele frequencies in total patients, control and Type 2 diabetic patients with nephropathy (DN+) or without 
nephropathy (DN-)
PAI-1 Control T2DM p OR (95%Cl) DN- DN+ p OR (95%Cl) 
  (n=130) (n=131)   (n=80) (n=51) 
  n (%) n (%)   n (%) n (%)
Genotype
 4G/4G  44 (34) 33 (25)  Reference 18 (22.5) 15 (29.4)  Reference
 4G/5G 44 (34) 16 (12) 0.049 0.485 (0.234–0.004) 11 (13.8) 5 (9.8) 0.342 0.545 (0.154–1.922)
 5G/5G 42 (32) 82 (63) 0.001 2.60 (1.450–0.671) 51 (63.8) 31 (60.8) 0.449 0.729 (0.322–1.652)
Alleles
 4G 132 (50.3) 82 (31) 4.176 Reference 47 (29) 35 (34) 0.400 Reference
 5G 126 (49.7) 180 (69)  2.299 (1.608–0.287) 113 (71) 67 (66)  0.796 (0.467–1.355)
*: Pearson Chi-square Test; CI: Confidence interval; OR: Odds ratio
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Table 3. Some biochemical characteristics of total patients, control and Type 2 diabetic patients with nephropathy (DN+) or without nephropathy (DN-)
   n Mean±SD Median (25%–75%)
Age DN- 80 57.45±11.71 58.50 (48.00–66.75)
  DN+ 51 63.01±13.79 63.00 (53.00–73.00)
 P   0.021**
  Control 130 57.50±16.26 55.00 (48.00–69.00)
  Total patients 131 59.61±12.80 61.00 (50.00–68.00)
 P   0.187**
BMI DN- 80 31.63±5.73 31.23 (27.34–34.64)
  DN+ 51 30.98±5.57 29.75 (26.37–36.32)
 P                           0.605**
  Control 130 26.84±5.15 26.29 (22.39–30.81)
  Total patients 131 31.38±5.66 31.14 (27.05–34.88)
 P   0.000**
Duration of diabetes DN- 80 5.77±4.75 5.00 (2.00–8.00)
  DN+ 51 9.01±7.84 7.00 (2.00–15.00)
 P   0.041**
  Control 130 0.00±0.00 0 (0–0)
  Total patients 131 7.05±6.32 5.00 (2.00–10.00)
 P   0.000**
HbAC1 DN- 80 7.95±8.06 6.75 (5.80–7.40)
  DN+ 51 6.78±1.78 6.60 (5.00–7.60)
 P   0.468**
  Control 130 6.87±6.46 6.10 (5.70–6.35)
  Total patients 131 7.50±6.41 6.70 (5.50–7.50)
 P   0.003**
Creatin DN- 80 0.70±0.10 0.69 (0.62–0.77)
  DN+ 51 1.73±1.94 1.04 (1.00–1.44)
 P   0.000**
  Control 130 0.76±0.27 0.73 (0.58–0.85)
  Total patients 131 1.10±1.30 0.78 (0.66–1.00)
 P   0.019**
Cholesterol DN- 80 208.37±56.25 196.50 (172.25–241.50)
  DN+ 51 181.41±43.28 176.00 (158.00–200.00)
 P   0.007**
  Control 130 180.09±40.09 178.00 (159.50–201.00)
  Total patients 131 197.87±53.08 187.00 (162.00–226.00)
 P   0.075**
HDL DN- 80 45.02±13.06 45.00 (34.70–53.07)
  DN+ 51 41.23±13.66 41.80 (33.00–45.00)
 P   0.058**
  Control 130 48.10±19.67 47.90 (36.90–58.70)
  Total patients 131 43.54±13.37 43.00 (34.00–51.00)
 P   0.035**
LDL DN- 80 125.42±45.90 118.00 (96.25–154.50)
  DN+ 51 117.35±37.82 110.00 (91.00–150.00)
 P   0.325**
  Control 130 112.23±37.22 111.00 (91.00–128.00)
  Total patients 131 122.28±42.96 112.00 (94.00–150.00)
 P   0.240**
Triglyceride DN- 80 188.70±125.54 154.50 (109.25–251.25)
  DN+ 51 167.70±98.75 150.00 (96.00–210.00)
 P   0.394**
  Control 130 137.92±73.74 117.00 (86.00–198.00)
  Total patients 131 180.52±115.90 150.00 (108.00–229.00)
 P   0.002**
SD: Standard deviation; **: Mann-Whitney Rank Sum Test. Median (25%-75%)
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to the genotypes, the analysis of the biochemical properties of the 
patient and control groups was carried out by the independent 
two-sample t-test. The comparison of controls, T2 DM patients, 
DN+ and DN- were performed using Pearson’s chi-square test ac-
cording to the distribution of genotypes. The Shapiro-Wilk test was 
used for the normality test. P-values below 0.05 were considered 
statistically significant.
RESULTS
Some individual features of the control group, DN- and DN+ pa-
tients are shown in Table 1. Gender (p:0.012), smoking (p:0.514), 
diabetic retinopathy (p:0.631), hypertension (p:0.249) and family 
history (p:0.743) were not found to differ significantly in T2 DM 
and diabetic nephropathy compared to the control group.
The distributions and allele frequencies of the PAI-1 gene in T2 DM 
and DN patients are shown in Table 2. In this research, we found 
the genotype frequencies of the PAI-1 rs1799889 polymorphism to 
be 34% 4G4G, 34% 4G5G, and 32% 5G5G in the control group 
and 25% 4G4G, 12% 4G5G, and 63% 5G5G in the patient group. 
The PAI-1 4G5G genotype was determined to differ statistically sig-
nificantly between the control group and T2 DM patients (p:0.001). 
The 5G5G genotype was observed to be significantly higher in 
the patient group. We found the genotype frequencies of PAI-1 
rs1799889 polymorphism to be 22.5% 4G4G, 13.8% 4G5G, and 
63.8% 5G5G for DN- patients and 29.4% 4G4G, 9.8% 4G5G, 
and 60.8% 5G5G for the DN+ patients. The difference in genotype 
frequencies between the T2 DM patients without nephropathy and 
with nephropathy was not statistically significant (p:0.449).
Some biochemical characteristics of controls, T2DM patients, DN- 
and DN+ patients are demonstrated in Table 3. Accordingly, cre-
atine and cholesterol were statistically different among DN- with 
DN+ patients (p:0.000, p:0.007, respectively). The age of DN+ was 
statistically lower in comparison with that of DN-. There were no 
Table 4. Distribution of PAI-1 Gene 4G/5G polymorphism genotypes according to some clinical parameters of controls and patients
Parameters  Group  Genotypes
   4G/4G 4G/5G 5G/5G 
   n n n
Number  Total patients 33 16 82
  Control 44 44 42
HbA1C (%)  Total patients 8.60±1.75 9.13±2.73 6.73±0.15
  Control 8.40±2.36 6.06±0.09 6.12±0.10
 Statistics  p*=0.943 p*=0.421 p=0.523
Cholesterol (mg/dl)  Total patients 199.79±9.92 212.56±11.16 194.25±0.15
  Control 180.81±5.94 187.55±10.15 171.52±9.27
 Statistics  p*=0.154 p*=0.045 p*=0.018
Triglycerides (mg/dl)  Total patients 185.63±16.12 161.93±20.02 182.10±14.35
  Control 140.63±14.07 134.86±15.72 138.28±18.37
 Statistics  p*=0.040 p*=0.018 p*=0.066
Systolic pressure  Total patients 135.15±4.01 140.00±5.84 136.34±2.39
  Control 123.63±1.40 117.27±2.29 120.95±3.01
 Statistics  p*=0.010 p*=0.000 p*=0.003
Diastolic pressure  Total patients 80.30±2.06 79.37±2.13 81.10±1.66
  Control 71.36±1.77 70.90±1.72 69.04±2.05
 Statistics  p*=0.003 p*=0.004 p*=0.001
Creatine  Total patients 0.89±0.28 1.57±2.44 1.10±1.25
  Control 0.71±0.18 0.83±0.37 0.77±0.25
 Statistics  p=0.036 p=0.626 p=0.226
HDL  Total patients 44.76±15.46 46.23±13.66 42.54±12.46
  Control 49.27±14.80 51.75±27.09 43.06±13.96
 Statistics  p=0.067 p=0.595 p=0.487
LDL  Total patients 128.42±47.32 135.56±45.34 117.22±40.27 
  Control 112.64±36.95 114.59±39.04 109.33±37.22
 Statistics  p*=0.194 p=0.169 p=0.731
p*: Independent two sample t-test
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significant differences between DN- and DN+ concerning the dura-
tion of diabetes (p=0.041), BMI (p:0.605), HbA1c (p:0.468), HDL 
(p:0.058), LDL (p:0.325) and triglyceride (p:0.394). No statistical 
differences were obtained between patients and controls with re-
gard to age (p:0.187), Cholesterol (p:0.075) and LDL (p:0.240).
No significant differences were determined between the patient 
and control groups concerning BMI (p:0.000), the duration of 
diabetes (p:0.000), HbA1c (p:0.003), creatinine (p:0.000), HDL 
(p:0.035), and triglyceride (p:0.002).
The distribution of some clinical parameters, according to geno-
types, is presented in Table 4 for controls and patients. No statis-
tically significant difference according to genotypes was detected 
regarding HDL, LDL, and HbA1C value. Furthermore, a statisti-
cally significant difference was detected concerning cholesterol in 
the 4G5G (p:0.045) and 5G5G (p:0.018) genotypes. Concern-
ing triglyceride, a statistically significant difference was revealed 
in the 4G4G (p:0.040) and 4G5G (p:0.018) genotypes. In terms 
of creatinine, a statistical difference was determined in the 4G4G 
(p:0.036) genotype. In terms of systolic and diastolic pressure, 
a statistically significant difference was detected in all genotypes 
(p-values for systolic pressure; 4G4G: 0.010, 4G5G: 0.000, 
5G5G: 0.003 and p-values for diastolic pressure; 4G4G: 0.003, 
4G5G: 0.004, 5G5G: 0.001, respectively).
DISCUSSION
The findings obtained in this study showed that the gender, smok-
ing, diabetic retinopathy, hypertension, and the family history 
rates of T2 DM patients with or without nephropathy were not 
significantly different from those of the control group. Consistent 
with our findings, another study reported no significant differences 
in T2 DM patients with or without nephropathy concerning age, 
gender, and BMI (6).
In our study, when each patient and control group was analyzed 
for the genotype distribution and allele frequency of PAI-1 4G5G, 
the genotype frequency was determined to be 4G4G 34%, 4G5G 
34% and 5G5G 32% for the control group, and as 4G4G 25%, 
5G5G 63% and 4G5G 12% for all patients. A statistically signif-
icant difference was determined between the groups concerning 
the frequency of genotypes.
In our study, when DN- and DN+ groups were analyzed con-
cerning the genotype distribution and allele frequency of PAI-1 
4G5G, no statistically significant differences were detected. Many 
studies have indicated inconsistent findings on the significance of 
the PAI-1 rs1799889 polymorphism as a genetic risk indicator 
of diabetic nephropathy or retinopathy (8, 16). Xue et al. (10) 
determined that the PAI-1 gene could be associated with the risk 
of DN of the 4G4G genotype. Xu et al. (7) concluded that the 
PAI-1 rs1799889 polymorphism was related to DN development 
and progression. In a meta-analysis study, Zhao argued that the 
PAI-1 rs1799889 polymorphism could be related to T2 DM de-
velopment (12). Saely et al. (17) studied the PAI-1 rs1799889 
polymorphism in T2 DM subjects and suggested that this poly-
morphism was related to T2DM.
In a few studies conducted on DN patients, researchers have report-
ed that the PAI-1 rs1799889 polymorphism is related to DN (4, 
7). Chang et al. (4) stated that the homozygous 5G allele in the PAI 
gene rs1799889 polymorphism was defined as a protective factor 
in the development of diabetes in obese diabetic and insulin resis-
tance patients. In a meta-analysis study, it was shown that the PAI-1 
4G allele could be a risk allele for DN sensibility in the Chinese popu-
lation (18). Unlike our results, Chen et al. (19) reported that the PAI-
1 rs1799889 polymorphism was not associated with T2 DM risk.
CONCLUSION 
In the literature review, it was observed that different results were 
presented in different populations regarding the relationship be-
tween this gene and T2 DM and DN. This may arise from the 
limited knowledge about heterogeneity in populations and the 
underlying mechanism. To our knowledge, no studies have been 
conducted on T2 DM and DN and the PAI-1 rs1799889 poly-
morphism in our country. In a population, it may be essential to 
determine which polymorphic variants are most important con-
cerning disease development and treatment and to make haplo-
type maps in different populations. Accordingly, the PAI-1 gene 
in the Eastern Black Sea Turkish population is associated with the 
rs1799889 polymorphism T2 DM, and this polymorphism can be 
used as a genetic biomarker of T2 DM in the Eastern Black Sea 
Turkish population.
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